Page 21 - Sun Pharma

Sun Pharma Advanced surges on licensing pact with Sun Pharma

SPARC was surged 7% to Rs 375, while Sun Pharma was up 1% at Rs 779 on the BSE.

Sun Pharma introduces anti-cancer product in Europe

Over the next few months, Sun Pharma will launch Gemcitabine InfuSMART across the Netherlands, the UK, Spain, Germany, Italy and France

Sun Pharma trades firm after board approves buyback of shares

The stock was trading flat at Rs 754 on the BSE, as compared to 3.5% fall in the S&P BSE Sensex.

Sun announces share buyback

On a year-on-year basis, Sun Pharma's stock is down 13.7%

Sun Pharma buyback offer a no-show

Given the offer size, it is hardly a blip on the screen

Sun Pharma bets on new products to boost US skincare products growth

Company has high hopes for tildrakizumab, an experimental psoriasis drug that recently completed late-stage trials

Sun Pharma gains ahead of board meet to mull share buyback proposal

The stock was up 2% at Rs 757 on the BSE.

2,839 bottles made by Sun Pharma Inc being recalled in US

The recall is due to failed dissolution specifications

Madras HC orders in favour of Sun Pharma in trademark dispute

The Court issued a permanent injunction against Cadila Healthcare using marks similar to Sun Pharma's particular trademark

Sun Pharma relaunches sunscreen brand to grow OTC business

Suncros will now be sold through both prescription and OTC mode

Sun Pharma launches sunscreen brand Suncros

Company has also signed former Miss India and actress Dia Mirza as Suncros' brand ambassador

Continue to remain opportunistic for acquisitions: Sun Pharma

Shanghvi said process of integrating Ranbaxy with Sun Pharma has commenced with a view to ensure business momentum and drive value creation

Sun Pharma sells two manufacturing plants in US to Frontida BioPharm

Sale part of drug maker's plans to consolidate its manufacturing facilities in US

Sun Pharma's results, forecast disappoint

Add to 'already weak' sentiments

Sun Pharma forecasts annual sales below estimates, shares fall

As it grapples with increased competition in the US as well as supply constraints

Sun Pharma posts results below estimates; stock cracks 4%

However, it posted 92% jump in net profit in Q4 2016 on a y-o-y basis on the back of strong revenue growth.

Sun Pharma expects 8-10% revenue growth in FY 17

Sun Pharma has also proposed a buyback of shares and its board will meet on June 23 to evaluate the proposal

Sun Pharma logs 92% profit growth

Posts Rs 1,713 cr profit, revenue up by 25%

Sun Pharma gets US subpoena over pricing of generic drugs

Department of Justice seeks information on pricing and marketing of generic drugs it sells in the US

Sun Pharma stock up 5.8% over subsidiary Taro's strong quarterly result

Taro reported 8.6% sales growth to $265 million; operating profit rose 18% to $181 million